CCR6 Antagonist Compounds for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective modulation of CCR6 function, which is implicated in inflammatory and immunoregulatory disorders such as psoriasis, asthma, and autoimmune diseases, highlighting the need for compounds that can specifically target and regulate CCR6 activity.
Innovation Solution
Development of compounds with the formula (I), which act as potent antagonists of the CCR6 receptor, offering superior pharmacokinetic properties and in vivo anti-inflammatory activity, thereby providing a therapeutic approach for CCR6-mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment of inflammatory and immunoregulatory disorders is provided, but effective modulation of CCR6 function is lacking
Solution Approach 1:
The patent employs parameter changes by developing compounds with specific molecular structures (Formula I) that have optimized pharmacokinetic parameters including oral bioavailability, metabolic stability, and binding affinity to CCR6. This resolves the contradiction by changing the chemical parameters of the therapeutic agents to achieve both reliable CCR6 modulation and specific targeting capability.
2Reliability
If compounds with formula (I) are developed, then potent CCR6 antagonism and superior pharmacokinetic properties are achieved, but complexity of compound synthesis increases
Solution Approach 1:
The patent applies segmentation by dividing the complex molecule of Formula I into modular synthetic intermediates and building blocks. The synthesis pathway is broken down into discrete steps with identifiable intermediates, making the manufacturing process more manageable despite the overall molecular complexity required for potent CCR6 antagonism and superior pharmacokinetics.
3Object-affected harmful factors
If CCR6 function is inhibited, then inflammatory responses are reduced and immune cell trafficking is regulated, but potential off-target effects on other chemokine receptors may occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features that confer selectivity for CCR6 over other chemokine receptors. The molecular structure of Formula I contains specific pharmacophoric elements that interact uniquely with CCR6 binding sites, enabling localized and specific modulation of CCR6 function while minimizing off-target effects on other receptors.
Data Source
AI summary
Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6: